Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $12.56 in the last session%, Up $2.87% from day before closing price of $12.21. In other words, the price has increased by $2.87 from its previous closing price. On the day, 2.42 million shares were traded. OCUL stock price reached its highest trading level at $12.648 during the session, while it also had its lowest trading level at $12.07.
Ratios:
We take a closer look at OCUL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.02 and its Current Ratio is at 10.09. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.24.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17.
On March 11, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.Needham initiated its Buy rating on March 11, 2025, with a $15 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when Waheed Nadia sold 13,861 shares for $8.05 per share. The transaction valued at 111,581 led to the insider holds 206,805 shares of the business.
NADIA K. WAHEED bought 13,861 shares of OCUL for $111,524 on Jun 02 ’25. On May 23 ’25, another insider, Nayak Sanjay, who serves as the Chief Strategy Officer of the company, sold 1,862 shares for $7.17 each. As a result, the insider received 13,351 and left with 281,623 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2185377280 and an Enterprise Value of 1871185024. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.57 while its Price-to-Book (P/B) ratio in mrq is 7.10. Its current Enterprise Value per Revenue stands at 33.022 whereas that against EBITDA is -7.885.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.50, which has changed by 0.57000005 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $12.65, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is 22.73%, while the 200-Day Moving Average is calculated to be 43.60%.
Shares Statistics:
According to the various share statistics, OCUL traded on average about 2.32M shares per day over the past 3-months and 2215240 shares per day over the past 10 days. A total of 172.93M shares are outstanding, with a floating share count of 145.44M. Insiders hold about 16.41% of the company’s shares, while institutions hold 68.07% stake in the company. Shares short for OCUL as of 1752537600 were 14797351 with a Short Ratio of 6.38, compared to 1749772800 on 14421637. Therefore, it implies a Short% of Shares Outstanding of 14797351 and a Short% of Float of 9.33.
Earnings Estimates
The company has 4.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.33 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.29 and -$1.62 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$1.37, with 4.0 analysts recommending between -$1.25 and -$1.59.
Revenue Estimates
According to 11 analysts, the current quarter’s revenue is expected to be $14.39M. It ranges from a high estimate of $19M to a low estimate of $12.56M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $15.43MFor the next quarter, 11 analysts are estimating revenue of $16.13M. There is a high estimate of $24.6M for the next quarter, whereas the lowest estimate is $13.5M.
A total of 11 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.8M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.69M. In the same quarter a year ago, actual revenue was $63.72MBased on 11 analysts’ estimates, the company’s revenue will be $65.92M in the next fiscal year. The high estimate is $82.9M and the low estimate is $52.3M.
